Maintenance therapy for advanced non-small-cell lung cancer

Switch versus continuation

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Introduction : The concept of maintenance therapy in lung cancer has stirred a great deal of interest over the last decade. Several randomized studies have been conducted to find out the usefulness of maintenance therapies for advanced non-small-cell lung cancer (NSCLC). Areas covered : This article reviews the major benchmark clinical trials and strategies in the field of maintenance chemotherapy in advanced NSCLC. The two strategies used in maintenance therapy are: i) continuation maintenance - continuation of one of the initial treatments; and ii) switch maintenance - switching to a different agent not administered as initial treatment. Both chemotherapeutic and molecular targeted agents have been studied in the maintenance setting. These include docetaxel, gemcitabine, pemetrexed, bevacizumab, erlotinib and gefitinib. This paper discusses the relevant clinical trials using these agents and the two different strategies in the maintenance therapy in advanced NSCLC. Expert opinion : Despite some controversy regarding the choice or the timing of the maintenance therapy, most of the clinical trials have demonstrated a significant improvement of progression-free survival, translating to a survival benefit with pemetrexed and erlotinib. The approval of pemetrexed and erlotinib by the FDA has certainly shifted the pendulum towards maintenance therapy.

Original languageEnglish (US)
Pages (from-to)685-697
Number of pages13
JournalExpert Opinion on Pharmacotherapy
Volume13
Issue number5
DOIs
StatePublished - Apr 1 2012

Fingerprint

Non-Small Cell Lung Carcinoma
Pemetrexed
Maintenance
Clinical Trials
docetaxel
Therapeutics
gemcitabine
Maintenance Chemotherapy
Benchmarking
Expert Testimony
Disease-Free Survival
Lung Neoplasms
Erlotinib Hydrochloride

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

@article{5d49bb5c6e914460a31d676d95f5953c,
title = "Maintenance therapy for advanced non-small-cell lung cancer: Switch versus continuation",
abstract = "Introduction : The concept of maintenance therapy in lung cancer has stirred a great deal of interest over the last decade. Several randomized studies have been conducted to find out the usefulness of maintenance therapies for advanced non-small-cell lung cancer (NSCLC). Areas covered : This article reviews the major benchmark clinical trials and strategies in the field of maintenance chemotherapy in advanced NSCLC. The two strategies used in maintenance therapy are: i) continuation maintenance - continuation of one of the initial treatments; and ii) switch maintenance - switching to a different agent not administered as initial treatment. Both chemotherapeutic and molecular targeted agents have been studied in the maintenance setting. These include docetaxel, gemcitabine, pemetrexed, bevacizumab, erlotinib and gefitinib. This paper discusses the relevant clinical trials using these agents and the two different strategies in the maintenance therapy in advanced NSCLC. Expert opinion : Despite some controversy regarding the choice or the timing of the maintenance therapy, most of the clinical trials have demonstrated a significant improvement of progression-free survival, translating to a survival benefit with pemetrexed and erlotinib. The approval of pemetrexed and erlotinib by the FDA has certainly shifted the pendulum towards maintenance therapy.",
author = "Monika Joshi and Yixing Jiang and Chandra Belani",
year = "2012",
month = "4",
day = "1",
doi = "10.1517/14656566.2012.668530",
language = "English (US)",
volume = "13",
pages = "685--697",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "5",

}

Maintenance therapy for advanced non-small-cell lung cancer : Switch versus continuation. / Joshi, Monika; Jiang, Yixing; Belani, Chandra.

In: Expert Opinion on Pharmacotherapy, Vol. 13, No. 5, 01.04.2012, p. 685-697.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Maintenance therapy for advanced non-small-cell lung cancer

T2 - Switch versus continuation

AU - Joshi, Monika

AU - Jiang, Yixing

AU - Belani, Chandra

PY - 2012/4/1

Y1 - 2012/4/1

N2 - Introduction : The concept of maintenance therapy in lung cancer has stirred a great deal of interest over the last decade. Several randomized studies have been conducted to find out the usefulness of maintenance therapies for advanced non-small-cell lung cancer (NSCLC). Areas covered : This article reviews the major benchmark clinical trials and strategies in the field of maintenance chemotherapy in advanced NSCLC. The two strategies used in maintenance therapy are: i) continuation maintenance - continuation of one of the initial treatments; and ii) switch maintenance - switching to a different agent not administered as initial treatment. Both chemotherapeutic and molecular targeted agents have been studied in the maintenance setting. These include docetaxel, gemcitabine, pemetrexed, bevacizumab, erlotinib and gefitinib. This paper discusses the relevant clinical trials using these agents and the two different strategies in the maintenance therapy in advanced NSCLC. Expert opinion : Despite some controversy regarding the choice or the timing of the maintenance therapy, most of the clinical trials have demonstrated a significant improvement of progression-free survival, translating to a survival benefit with pemetrexed and erlotinib. The approval of pemetrexed and erlotinib by the FDA has certainly shifted the pendulum towards maintenance therapy.

AB - Introduction : The concept of maintenance therapy in lung cancer has stirred a great deal of interest over the last decade. Several randomized studies have been conducted to find out the usefulness of maintenance therapies for advanced non-small-cell lung cancer (NSCLC). Areas covered : This article reviews the major benchmark clinical trials and strategies in the field of maintenance chemotherapy in advanced NSCLC. The two strategies used in maintenance therapy are: i) continuation maintenance - continuation of one of the initial treatments; and ii) switch maintenance - switching to a different agent not administered as initial treatment. Both chemotherapeutic and molecular targeted agents have been studied in the maintenance setting. These include docetaxel, gemcitabine, pemetrexed, bevacizumab, erlotinib and gefitinib. This paper discusses the relevant clinical trials using these agents and the two different strategies in the maintenance therapy in advanced NSCLC. Expert opinion : Despite some controversy regarding the choice or the timing of the maintenance therapy, most of the clinical trials have demonstrated a significant improvement of progression-free survival, translating to a survival benefit with pemetrexed and erlotinib. The approval of pemetrexed and erlotinib by the FDA has certainly shifted the pendulum towards maintenance therapy.

UR - http://www.scopus.com/inward/record.url?scp=84863392951&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863392951&partnerID=8YFLogxK

U2 - 10.1517/14656566.2012.668530

DO - 10.1517/14656566.2012.668530

M3 - Review article

VL - 13

SP - 685

EP - 697

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 5

ER -